^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | BDTX-1535 (EGFR inhibitor, EGFR MasterKey inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3396 / 6 - Discovery of BDTX-1535, a novel 4th generation, irreversible, potent, wild type sparing EGFR MasterKey inhibitor that targets oncogenic kinase domain mutations as well as extracellular domain alterations for the treatment of NSCLC and GBM
Published date:
03/15/2023
Excerpt:
BDTX-1535 achieves potent anti-tumor activity against EGFR alterations and amplification across models including NSCLC and GBM PDX and intracranial tumors.
Title:
Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting
Published date:
11/20/2020
Excerpt:
...in vivo data that showed tumor growth inhibition in intracranial patient-derived xenograft (PDX) tumor models expressing allosteric EGFR mutants, supports the potential for BDTX-1535 to meaningfully transform the treatment paradigm for patients with GBM.”
